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Abstract 
Background: CD44 has recently been reported as a cancer stem cell marker in ovarian cancer. However, the clinico-
pathological and prognostic value of this marker in ovarian cancer remains controversial; Here, we aimed to inves-
tigate the correlation between CD44 expression and the clinicopathological features or survival of ovarian cancer 
patients.
Methods: An extensive literature search in the PubMed, EMBASE, and Wanfang databases (up to June 1, 2016) was 
conducted to identify studies that assessed the clinical or prognostic significance of CD44 expression in ovarian can-
cer. A meta-analysis was then performed to clarify the association between CD44 expression and clinical outcomes of 
ovarian cancer patients.
Results: A total of 18 publications consisting of 2161 patients were included for this meta-analysis. Our data reveal 
that CD44-positive expression in ovarian cancers were significantly associated with a high TMN stage (pooled 
OR = 2.11, 95% CI 1.26–3.53, P = 0.004) and poor 5-year overall survival (RR = 1.42, 95% CI 1.01–2.00, P = 0.05). How-
ever, CD44 expression was not associated with tumor grade, lymphatic metastasis, age of the patients, residual tumor 
size, response to chemotherapy, or ascites volume (P > 0.05).
Conclusion: Detection of CD44 may be an effective tool for pathological diagnosis and prognostic prediction of 
ovarian cancer patients in clinical applications.
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Background
Ovarian cancer is the leading cause of death from 
gynecologic malignancy [1]. Although most ovarian 
cancer patients initially respond very well to platinum-
based chemotherapy, the vast majority of patients will 
ultimately develop cancer recurrence and succumb to 
chemo-resistant disease [1].
CSCs represent a subpopulation of cancer cells that 
possess tumor initiation and self-renewal capacity and 
have been implicated in driving tumor growth, metas-
tasis, and relapse following therapy in a wide variety of 
human cancers such as breast and ovarian cancers [2, 3]. 
In recent years, CSCs have also been found to contribute 
to the poor clinical outcome of ovarian cancer patients 
[4]. Furthermore, it has been suggested that CSC mark-
ers, such as CD44, ALDH1 and CD133, may serve as 
valuable prognostic indicators for ovarian cancer [4, 5]. 
Among these CSC markers, CD44 is the most frequently 
reported in ovarian cancer. Several studies have demon-
strated that CD44 can be used to isolate cancer cells with 
stem cell-like and cancer-initiating properties from other 
populations of cancer cells [6–8].
CD44, which consists of four functional domains, plays 
important roles in cell–matrix adhesion, signal transduc-
tion, cytoskeletal rearrangement, and cell migration [9]. 
Intriguingly, the proximal extracellular domain is the site 
for alternative splicing of the CD44 mRNA that results 
in various isoforms of CD44. The CD44 standard form 
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(CD44s) and CD44 variants (CD44v) participate in cell–
cell and cell–matrix interactions, cell migration, lympho-
cytehoming, and tumorigenesis. CD44v6 has particularly 
gained a lot of attention in recent years, since the expres-
sion of this variant has been found to be upregulated in a 
variety of epithelial malignancies, such as head and neck, 
colon, endometrium and ovarian cancers. CD44v6 may 
be implicated in the activation of PI3K/Akt and MAPK 
pathways, which can then inhibit apoptosis and promote 
invasion and metastasis of cancer cells [10–14].
Although the association between the expression of 
CD44 or its isoforms and the survival of patients with 
ovarian cancer has been well investigated, the prognos-
tic values of CD44, CD44s, and CD44v6 in predicting 
the survival of patients with ovarian cancer remains con-
troversial [15–19]. In the present study, we performed 
a systematic review and meta-analysis of the published 
literature to examine the association of the expression 
of CD44 or its isoforms with the clinicopathological fea-
tures and the prognosis of ovarian cancer patients. These 
findings may help to uncover valuable marker that may 
enable the prognostic stratification of ovarian cancer 




The electronic databases, including Pubmed, Embase, 
and Wanfang, were searched for studies that investi-
gated the correlation of the CD44 expression and clinico-
pathological parameters and prognosis in ovarian cancer 
patients. The literature search was updated until June 
1, 2016. The search terms were used as follows: “CD44”, 
“ovarian neoplasms” or “ovary neoplasms” or “ovarian 
cancer” or “cancer of ovary”. Review articles and the cita-
tions from all the retrieved reports were further manu-
ally reviewed to identify other relevant publications. The 
titles and abstracts of identified reports were examined 
to exclude any irrelevant publications. The full-text of the 
remaining articles were further inspected to determine 
whether they reported the correlation of the expression 
of CD44 or its isoforms and the clinicopathological fea-
tures and prognosis of ovarian cancer patients.
Inclusion and exclusion criteria
The studies included for this meta-analysis met the fol-
lowing criteria: (1) Definitive diagnosis of ovarian cancer 
was made on the basis of histopathological findings; (2) 
Studies that examined the protein expression of CD44, 
CD44s, or CD44v6 in ovarian tissues instead of that in 
the serum or any other types of specimen; (3) studies that 
investigated the correlation of the expression of CD44, 
CD44s, or CD44v6 with clinicopathological features; 
(4) studies that reported the association of the expres-
sion of CD44 or its isoforms with overall survival (OS) of 
ovarian cancer patients. There was no limitation on the 
minimum number of patients in each study. When there 
were multiple articles by the same group based on similar 
patient populations, only the largest or the most recent 
article was included. The exclusion criteria for this meta-
analysis include: (a) Studies were not associated with the 
topic of interest; (b) researchers did not make the defini-
tive diagnosis based on histopathologic findings or they 
did not carried out clinical and imaging follow-up for at 
least 6 months; (c) studies associated with other diseases 
(d); non-original articles; (e) data could not be extracted; 
and (f ) duplicate data from the same or similar patient 
population.
Data extraction
The following information was extracted from the 
retrieved full-text papers: lead author, country of the 
patients, ethnicity, publication year, time of sample col-
lection, the pathological stages of tumors, number of 
patients, types of research techniques, the ages of the 
patients, and the choice of cut-off scores for the defi-
nition of positive staining or staining intensity. The 
included studies can be divided into two major groups 
based on the research objectives of these studies. One 
group evaluated the correlation between the expression 
of CD44, CD44s, or CD44v6 and the clinicopathological 
parameters, including TMN stage, tumor grade, lym-
phatic metastasis, age of the patients, residual tumor 
size, responses to chemotherapy, and ascites volume. 
The other group investigated the association between the 
expression of CD44, CD44s, or CD44v6 and the OS or 
disease-free survival (DFS).
Statistical analysis
The meta-analysis was performed as previously described 
[20]. Odds ratios (ORs) with 95% confidence interval (CI) 
were employed to evaluate the association between the 
expression of CD44, CD44s, or CD44v6 and the clinico-
pathological features for the patients with ovarian cancer, 
including TMN stage, tumor grade, lymphatic metasta-
sis, age of the patients, residual tumor size, responses to 
chemotherapy, and ascites volume. By contrast, the risk 
ratio (RR) was used for assessing the correlation of the 
expression of CD44, CD44s, or CD44v6 and the OS or 
DFS. If RRs were not reported directly in the published 
articles, the data from those papers were then used to 
calculate the RR according to the methods described by 
Parmar et al. [21]. Heterogeneity across studies was eval-
uated with the Q test and P values. ORs and RRs were 
calculated using a random-effects model when the P 
value was less than 0.05. Otherwise, a fixed-effects model 
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was applied. The Begg’s funnel plot and Egger’s test were 
used to assess publication bias. All statistical analyses 
were carried out using Review manager software (Rev-
man version 5.3.5.). The difference will be considered sta-
tistically significant when two-sided P values are less than 
0.05.
Results
Characteristics of the included studies
A total of 451 articles were originally identified for 
the meta-analysis after searching the electronic data-
bases PubMed, Embase, and Wanfang. 421 reports were 
excluded after closely reviewing the titles and abstracts. 
Eventually, the extensive review of the full-text articles 
yielded a total of 18 studies consisting of 2161 patients 
that met the inclusion criteria for this meta-analysis [15–
19, 22–34] (Fig. 1). The main characteristics of the eligible 
studies are summarized in Table 1. Among the included 
studies, 17 articles assessed the correlation between the 
expression of CD44 or its isoforms and the clinicopatho-
logical features of ovarian cancer, whereas the association 
of CD44 expression with OS or DFS was examined using 
the Kaplan–Meier method in 12 of these studies.
The correlation of CD44v6 expression 
with clinicopathological parameters
Notably, our analysis based on the random-effect model 
reveals that the expression of CD44v6 in ovarian can-
cers is significantly associated with a high TMN stage 
(pooled OR = 2.11, 95% CI 1.26–3.53, P = 0.004) (Fig. 2). 
However, there is no significant correlation between 
CD44 expression and tumor grade (pooled OR  =  2.08, 
95% CI 0.91–4.74, P  =  0.08, random-effect model) 
(Fig.  3), lymphatic metastasis (pooled OR  =  1.76, 95% 
CI 0.78–3.95, P  =  0.17, random-effect model) (Fig.  4), 
age of the patients (pooled OR = 1.60, 95% CI 0.58–1.93, 
P = 0.84, fixed-effect model) (Fig. 5), residual tumor size 
(pooled OR = 1.01, 95% CI 0.30–3.40, P = 0.99, random-
effect model) (Fig. 6), response to chemotherapy (pooled 
OR =  2.71, 95% CI 0.90–8.22, P =  0.08, random-effect 
model) (Fig. 7), or ascites volume (pooled OR = 1.61, 95% 
CI 0.66–3.94, P = 0.29, random-effect model) (Fig. 8).
The correlation between CD44 expression and the 
prognosis of ovarian cancer
Next, we analyzed the impact of CD44 expression on the 
survival of ovarian cancer patients. As shown in Fig.  3, 
our meta-analysis of the pooled data from the ten stud-
ies showed that CD44 expression is significantly associ-
ated with a poor 5-year OS (RR = 1.42, 95% CI 1.01–2.00, 
P = 0.05) (Fig. 9). Nevertheless, CD44 expression is not 
significantly correlated with DFS (RR  =  1.23, 95% CI 
0.86–1.77, P < 0.25) (Fig. 10).
Sensitivity analysis
In order to rule out a bias introduced by the low num-
bers of eligible publications for our meta-analysis, we 
then performed a sensitivity analysis. For this purpose, 
an individual study included in the meta-analysis was 
removed for each round of analysis to investigate the 
influence of the single dataset of the particular study on 
the pooled ORs. Our data suggest that the corresponding 
pooled ORs were not significantly altered by the removal 
of any study (data not shown), indicating that our results 
are statistically robust.
Publication bias
Next we evaluated the publication bias regarding our 
meta-analysis using Begg’s funnel plot and Egger’s test. 
The Begg’s funnel plots of the meta-analyses of the cor-
relation between CD44 expression and the clinicopatho-
logical parameters and 5-year OS or DFS did not show 
an evident asymmetrical shape. Consistently, the results 
of Egger’s test also rule out publication bias involving our 
meta-analysis (Table 2).
Discussion
It has been hypothesized that the formation and progres-
sion of cancers are driven by CSCs which represent a 
minor population in cancer cells [35]. More importantly, 
CSCs are considered to be responsible for chemother-
apy resistance, metastasis, and postoperative recurrence 
[36]. A significant fraction of ovarian cancer patients Fig. 1 The flow diagram of article selection
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will ultimately develop cancer recurrence and succumb 
to chemo-resistant disease [37]. Furthermore, to date, 
there are still no reliable markers available for the diag-
nosis and prognosis of ovarian cancer patients. There-
fore, it remains urgent to search for a reliable prognostic 
parameter applicable in clinical practice to predict dis-
ease outcomes in ovarian cancer. CD44 is an important 
cell surface marker for isolating CSCs from tumors and 
is correlate with poor prognosis in various human can-
cers [7, 38–40]. Intriguingly, in this study, we found that 
the expression of CD44v6 in ovarian cancers is signifi-
cantly associated with a high TMN stage. Moreover, our 
findings revealed that CD44 expression is inversely cor-
related with a poor 5-year OS. However,we find no sig-
nificant association between CD44 positivity and tumor 
grade, lymphatic metastasis, age of the patients, residual 
tumor size, response to chemotherapy, or ascites volume. 
These data indicate that CD44 expression may be used in 
the pathological evaluation of tissue histology to predict 
ovarian cancer prognosis in the future.
CD44 was identified as a surface glycoprotein and a 
lymphocyte homing receptor found on lymphoid and 
epithelial cells in 1982 [41]. Its main function on lym-
phocytes is mediating interaction with the endothelium 
[42]. Substantial evidence indicates that CD44 has been 
implicated in cancer invasion and metastasis. CD44v6, 
one of the major variants of CD44, could modulate the 
conjugation of CD44s and hyaluronic acid (HA), or 
enhance the metastasis of tumor by conjugating with HA 
[43]. CD44 plays an essential role in epithelial mesenchy-
mal transition (EMT), one of the most important events 
in the cancer invasion process [44, 45]. Consistently, in 
some epithelial cells, the EMT process was accompa-
nied by CD44 isoform switch from CD44v6 to CD44s, 
and CD44s has been proved to promote the EMT pro-
cess [46]. Moreover, CD44 also plays a critical role in cell 
migration. After activated by its binding to hyaluronan, 
the cytoplasmic tail of CD44 in turn bind to the actin 
cytoskeleton and it would be translocated to the lead-
ing edge of the migrating cells. Thereafter, CD44 binds 
to CD62 on the endothelial cells, enabling the migrating 
cells to roll on the endothelia cells, which is the initial 
step of cell migration named extravasation [47]. Because 
of the important role that CD44 plays in cancer invasion 
Fig. 2 Forest plot depiction of CD44 expression and TMN stage
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Fig. 3 Forest plot depiction of CD44 expression and tumor grade
Fig. 4 Forest plot depiction of CD44 expression and lymphatic metastasis
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Fig. 5 Forest plot depiction of CD44 expression and age of the patients
Fig. 6 Forest plot depiction of CD44 expression and residual tumor size
Fig. 7 Forest plot depiction of CD44 expression and response to chemotherapy
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Fig. 8 Forest plot depiction of CD44 expression and ascites volume l(G)
Fig. 9 Forest plot illustrates the association between CD44 expression and OS of ovarian cancer
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and metastasis, it has been suggested that the expression 
of CD44 or certain CD44 variants could serve as valuable 
candidates for early detection, or as a prognostic predic-
tor for gynecologic malignancies. Although some studies 
reported that high levels of CD44 expression was associ-
ated with a poor prognosis in ovarian cancer patients [17, 
28], On the contrary, other groups concluded that CD44 
expression had no influence on the survival of patients 
with ovarian cancer [15, 27]. This inconsistency may 
result from small sample size in each individual study. 
Here, we summarized the pooled data from these studies 
to increase the statistical power and better evaluate the 
prognostic values of the expression status of CD44 and 
its variants in ovarian cancer. To the best of our knowl-
edge, this is the first meta-analysis of published data to 
evaluate the association between CD44 expression and 
prognosis in ovarian cancer.
It is important to note that there may be some potential 
limitations regarding our meta-analysis. First, variation 
in definitions of clinical outcomes, measurements and 
experimental procedures might contribute to between-
study heterogeneity. It is particularly difficult to address 
the issue of variations in the definitions of clinical out-
comes among different studies. Second, potential pub-
lication bias may also be a concern. We restricted our 
review to articles published in English or Chinese lan-
guage because other languages were not accessible to the 
readers, which could favor the positive data that are more 
often published in English while the negative ones tend 
to be more often reported in other native languages.
Conclusion
Our findings demonstrate that CD44 expression is asso-
ciated with a higher tumor TNM stage among ovarian 
cancer patients. Moreover, ovarian cancer patients with 
positive CD44 expression exhibit a worse clinical out-
come than those with negative CD44 expression. Further 
studies with larger sample sizes will be warranted to vali-
date the findings of our meta-analysis in the future.
Fig. 10 Forest plot illustrates the association between CD44 expression and DFS of ovarian cancer
Table 2 Egger’s test of funnel plot asymmetry
df deflection
Clinicopathological parameters t value df P value
Tumor differentiation 1.78 12 0.484
Tumor TNM stage 1.08 16 0.714
Primary residual tumor 0.66 3 0.997
Response to chemotherapy 3.42 3 0.174
Age 6.15 4 0.142
Lymphatic metastasis 2.97 5 0.243
Histology 0.66 8 0.322
Ascites 0.67 4 0.327
Overall survival 2.26 11 0.531
Disease free survival 0.21 4 1.000
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